The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked CRA to review the evidence on the developments concerning access to antiretroviral drugs (ARVs) for the treatment of HIV/AIDS over the last 10 years in low- and middle-income countries, the factors that have contributed to progress, and the lessons that these offer for the future. Vice President Tim Wilsdon, Senior Consultant to CRA Dr. Jim Attridge, and Associate Hugh Kirkpatrick discuss these findings in their article. To read it, click here:
Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant...